Cable news

Comcast unveils its $16 million technology center in a growing suburb just outside of Houston

The new $16 million Comcast facility is another feather in the cap of Fort Bend County, which is booming with new business. Courtesy of Comcast

At Comcast's new $16 million technology center in Missouri City, technicians for the internet and cable TV provider can "test drive" new product and services at a demo lab and can take classes at Comcast University. It's a far cry from the stereotypical workplace of the "cable guy."

The center represents a cutting-edge expansion for Comcast — and represents yet another feather in the economic-growth cap of Missouri City and Fort Bend County.

On June 19, officials from Comcast, Missouri City government, and the Fort Bend Economic Development Council debuted the 32,000-square-foot center. The center is at 551 Buffalo Lakes Dr., near the intersection of Texas Freeway and Independence Boulevard. Aside from the demo lab and Comcast University classrooms, the center features more than 100 workstations and 15 conference rooms.

The center employs more than 300 technicians, Comcast Business and Xfinity sales professionals. Service technicians install and maintain internet, video, voice, and home security services for residential and business customers in Missouri City and nearby areas, while network technicians build and maintain Comcast's local fiber-optic system.

Employees at the new center previously worked at other offices in the Houston metro area but live in Missouri City and surrounding communities. More than 1,200 people work at Comcast's 10 technology centers throughout the Houston area.

Michael Bybee, director of external communications at Comcast, says Missouri City was picked for the new center because of its strong economic growth and its proximity to major highways and, ultimately, "to bring our employees closer to customers."

Missouri City and Fort Bend County are gaining more potential Comcast customers by the day. From April 2010 to July 2018, the population of Missouri City grew 12.3 percent, according to the U.S. Census Bureau. For Fort Bend County, the population growth rate during the same period stood at 34.7 percent.

Economic growth has accompanied that population growth. Last year, the Comcast center was among several economic development wins scored by Missouri City. An $85 million, 550,000-square-foot Best Buy distribution center and a 200,000-square-foot Warren Valve warehouse and distribution center were two of the other wins.

Fort Bend County as a whole is enjoying economic success. For instance, discount retailer Dollar Tree said in February that it's building a $130 million distribution center on a 140-acre site in Rosenberg that will employ more than 300 people. The company operates more than 1,600 Dollar Tree and Family Dollar stores in Texas.

The 1.2-million-square-foot distribution center, on Spur 10 near Klosterhoff Road, is scheduled to open in the summer of 2020.

"When you have a company like Dollar Tree seeing the opportunity that we offer, it just adds to our strengths and builds on our assets," Bret Gardella, executive director of Rosenberg Development Corp., said in a Dollar Tree news release.

The economic growth in Missouri City, Rosenberg and other places in Fort Bend County isn't likely to subside, at least for the next several decades. A report from the University of Houston's Hobby School of Public Affairs predicts Fort Bend County will end up being the state's third-fastest-growing county from 2010 to 2050.

"Fort Bend County has continued to top lists for livability and economic success — and there is no sign of slowing down," the Fort Bend Economic Development Council says on its website. "Residents and businesses agree that there's no place better to live or work."

Contributing to Fort Bend County's draw is the presence of five business parks — two in Missouri City, and one each in Rosenberg, Sugar Land, and Stafford. The council touts Fort Bend County as "the hub for industrial development."

Courtesy of Comcast

Aside from the demo lab and Comcast University classrooms, the center features more than 100 workstations and 15 conference rooms.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News